PATIENT EXPERIENCE OF PEMBROLIZUMAB (KEYTRUDA)

[RoyCastleHelpline]

PEMBOLIZUMAB (KEYTRUDA) will shortly be assessed by the Scottish Medicine Consortium (SMC) for use in NHS Scotland with two indications:

1. In combination with platinum-based chemotherapy for the neoadjuvant (treatment given before surgery) and then continued as monotherapy (single treatment) for the treatment of resectable non-small cell lung cancer at high risk of recurrence in adults.

2. Monotherapy for the adjuvant (after surgery) treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

We have been invited to provide a Patient Group Submission for each of the indications of this medicine, and are therefore trying to gather some patient experience quotes in support for this proposed treatment; you do not have to live in Scotland to comment and it would be extremely helpful to know the following:

What was your experience of Pembrolizumab, any side effects and were they managed well.

How did being on Pembrolizumab affect your quality of life?

If you have had adjuvant treatment after surgery, what was your experience?

Would you have preferred to have treatment before surgery?

If you are happy to comment on any of the questions, please get in touch, no personal details are needed, but discussing it with you will help us put together the document on behalf of patients.

Please either comment below, private message or email [e-mail], alternatively, you can phone the Roy Castle Ask the Nurse service on 0800 358 7200

All comments are welcome, so please do get in touch.

Thank you in advance.

The Roy Castle Support Team